Zaiding Pharmaceuticals (09688) rose more than 5%. As of press release, it rose 5.26% to HK$20.8, with a turnover of HK$7.8692 million.
The Zhitong Finance App learned that Zaiding Pharmaceutical (09688) rose by more than 5%. As of press release, it had risen 5.26% to HK$20.8, with a turnover of HK$7.8692 million.
According to the news, on November 21, Pfizer and Zaiding Pharmaceuticals announced that the two sides have reached a strategic cooperation on the novel antimicrobial drug Dingyule (sulbactam sodium-dulobactan sodium) in mainland China. Pfizer's company is solely responsible for the commercial operation of this product in mainland China. The novel antimicrobial drug Dingyule is currently the only antimicrobial drug specially developed to treat acinetobacter baumannii (CRAB), which is resistant to carbapenems. The product was approved in the US and mainland China in 2023 and 2024, respectively.